Generic Name and Formulations:
Naltrexone HCl 50mg; scored tabs.
Indications for REVIA:
Adjunct in treatment of alcohol or narcotic dependence.
Confirm 7–10 day opioid-free period, if questionable do Narcan challenge test (see literature). ≥18yrs: Alcoholism: 50mg daily. Narcotic dependence: Initially 25mg, if no withdrawal symptoms increase to 50mg daily; alternative dosing schedules: see literature.
<18yrs: not recommended.
Concomitant opioids, current opioid dependence, or acute opioid withdrawal. Failed Narcan challenge test or (+) urine screen for opioids. Acute hepatitis. Liver failure.
Liver disease. Monitor liver function. Warn patients of danger of attempting to overcome opiate blockade. Severe renal dysfunction. Possible acute abstinence syndrome. Depression. Suicidal ideation. Pregnancy (Cat.C). Nursing mothers.
Thioridazine increases sedation. Antagonizes opioids (eg, antitussives, antidiarrheals, analgesics). Disulfiram.
Hepatotoxicity, withdrawal reactions; others, see literature.
Sign Up for Free e-newsletters
Psychiatry Advisor Articles
- Lithium Monotherapy Effective in Treating Bipolar Disorder in Children
- Transdermal Nicotine Boosts Mood and Cognitive Function in Late-Life Depression
- Computerized Training Programs for Schizophrenia Improve Cognitive Functioning
- Cognitive Behavioral Therapy May Alter Suicidal Ideation in Anxiety Disorders
- Emerging Theories in the Pathophysiology of MDD: Could the Opioid System Be Involved?
- Antidepressant Effects of Ketamine Appear to Require Opioid System Activation
- Attention-Deficit/Hyperactivity Disorder Increasing Among US Children and Adolescents
- Cost-Effective Telehealth Alternatives for Veterans With Depression
- Polygenic Risk Scores Could Aid in Identifying Bipolar Disorder, Schizophrenia
- Brief Impression Questionnaire Useful in Schizophrenia Diagnoses